Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components

NCT01276327 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Linagliptin + Pioglitazone
DRUG: Linagliptin + Pioglitazone
DRUG: Linagliptin/Pioglitazone
DRUG: Linagliptin/Pioglitazone

Sponsor

Boehringer Ingelheim